Biota in new Hep C partnership with Glaxo
12 August, 2002 by Melissa TrudingerBiota Holdings' US subsidiary Biota Inc has announced a collaboration with GlaxoSmithKline (GSK) to develop new drugs against Hepatitis C, using Biota Inc's proprietary Numax technology platform.
BresaGen wins FDA approval for catheter
08 August, 2002 by Tanya HollisIn a step towards improved application of cell therapies, South Australian company BresaGen has gained US Food and Drug Administration approval to market a catheter designed for the delivery of therapeutics to the brain.
Chemeq raises $8m
07 August, 2002 by Melissa TrudingerChemeq has raised $8 million in its latest placement to institutions and other sophisticated investors, bringing the total raised this year to $15.5 million.
Skin surface laser patent granted to Norwood
07 August, 2002 by Tanya HollisDrug delivery group Norwood Abbey has added another patent to its portfolio, the latest covering laser technology to alter the skin's surface.
Mayne backs new brain centre
07 August, 2002 by Tanya HollisA new Sydney imaging centre is set to improve research opportunities for brain and nervous system specialists.
EQiTX, Starphama appoint heavy hitters
06 August, 2002 by Tanya HollisBorn-again oil exploration company EQiTX has added another science heavyweight to its ranks for its latest incarnation as a biotech.
Aventis CropScience becomes Bayer CropScience
06 August, 2002 by Melissa TrudingerAventis CropScience has officially become Bayer CropScience as a result of last year's acquisition of the CropScience unit by Bayer for around 7.25 billion euros ($AU13.4 billion).
Gradipore's Texan work nears completion
06 August, 2002 by Tanya HollisSydney bioseparations specialist Gradipore has revealed that the first stage of its collaborative work with Texas A&M University is nearing completion.
Prima applies for animal model patent
02 August, 2002 by Tanya HollisInflammatory diseases researcher Arthron has lodged a patent application over an animal model of arthritis with which to test potential new treatments.
pSivida rated 'speculative buy'
02 August, 2002 by Tanya HollisBrokers have rated biomaterials platform technology group pSivida a speculative buy following a recent joint venture with Singapore General Hospital.
NZ: post-election, GM hangs in the balance
02 August, 2002 by Tanya HollisThe post-election future of genetic modification in New Zealand hangs in the balance with the Labour Party still to determine the structure of its government.
BioStart money confirmed for Mimetica
01 August, 2002 by Pete YoungBrisbane drug design company Mimetica is the first recipient of funds from Queensland's $6 million BioStart pre-seed fund, as foreshadowed by Australian Biotechnology News in June.
von Itzstein named as Federation Fellowship winner
01 August, 2002 by Pete YoungOnly one biotech luminary, drug discovery researcher Prof Mark von Itzstein, made the list the list of 11 Federation Fellowship winners announced this week by Health Minister Brendan Nelson.
BresaGen claims stem cell breakthrough
01 August, 2002 by Melissa TrudingerAdelaide-based company BresaGen has claimed a stem cell breakthrough, announcing that the company had successfully derived neural precursor cells from human embryonic stem cell lines.
Cryosite profit aims ahead of target
01 August, 2002 by Iain ScottPrivate cord blood storage service Cryosite has said it now does not expect to have to go through another round of fund-raising to achieve profitability.
